Tada, thanks for the interesting post and perspective. Helps me fill in the blanks.

I certainly agree with your POV expressed below and it concerns me that the thinking I've heard re BoM2 seems reflective of the inability to raise money for a properly powered trial and futility analysis as needed. This is the Achilles heel at RVX.

tada wrote - "From observation, what has been consistent through the years though, is trying to cheap out on the science side while paying market or higher on the management side."

GLTA

Toinv